Aarti Drugs Ltd

BSE: 524348

166

total announcements

AARTIDRUGS.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 27 Oct 2026

Market Cap

₹3,462 Cr

P/E (TTM)

18.1

P/E (Forward)

13.6

EPS (TTM)

₹20.93

52W Low

₹318.95

52W High

₹534.00

Dividend Yield

0.53%

Beta

0.31

Price / Book

2.2

Debt / Equity

37.2

Revenue (TTM)

₹2,678 Cr

Gross Margin

37.52%

Operating Margin

11.46%

Announcements Discussion

BSECompany UpdateMgmt Change30 Sept 2026

AARTI DRUGS LIMITED

AARTI DRUGS LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr> <tr><td ....

AARTI DRUGS LIMITED has informed BSE about the cessation of its Chief Financial Officer.

BSECompany UpdateMgmt Change30 Sept 2026

AARTI DRUGS LIMITED

AARTI DRUGS LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr> <tr><td ....

Aarti Drugs Limited has informed the BSE about the cessation of its Executive Director.

BSECompany UpdateMgmt Change30 Sept 2026

AARTI DRUGS LIMITED

AARTI DRUGS LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr> <tr><td ....

Aarti Drugs Limited has informed BSE about the cessation of its Chief Financial Officer.

BSECompany UpdateMgmt Change30 Sept 2026

AARTI DRUGS LIMITED

AARTI DRUGS LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr> <tr><td ....

AARTI DRUGS LIMITED has informed BSE about the cessation of its Executive Director.

BSECompany UpdateMgmt Change30 Sept 2026

AARTI DRUGS LIMITED

AARTI DRUGS LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr> <tr><td ....

Aarti Drugs Limited has informed the BSE about the cessation of its Chief Financial Officer.

BSECompany UpdateMgmt Change30 Sept 2026

Aarti Drugs Ltd

Change in Directorate/ Management

Aarti Drugs Ltd has announced changes in its directorate and management, with Shri Prakash M. Patil ceasing to hold the positions of Chairman, Managing Director, and Chief Executive Officer, and Shri Adhish P. Patil relinquishing the position of Chief Financial Officer to take up the role of Managing Director.

Closure of Trading Window

Aarti Drugs Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its financial results for the quarter and half year ended September 30, 2026.